Head-To-Head Review: GRI Bio (NASDAQ:GRI) versus Seaport Therapeutics (NASDAQ:SPTX)

GRI Bio (NASDAQ:GRI) and Seaport Therapeutics (NASDAQ:SPTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.

Profitability

This table compares GRI Bio and Seaport Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GRI Bio	N/A	-156.24%	-116.90%
Seaport Therapeutics	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent recommendations and price targets for GRI Bio and Seaport Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRI Bio	1	0	1	0	2.00
Seaport Therapeutics	2	3	5	0	2.30

GRI Bio currently has a consensus price target of $32.00, indicating a potential upside of 1,816.17%. Seaport Therapeutics has a consensus price target of $38.40, indicating a potential upside of 58.55%. Given GRI Bio’s higher possible upside, analysts clearly believe GRI Bio is more favorable than Seaport Therapeutics.

Institutional & Insider Ownership

34.0% of GRI Bio shares are held by institutional investors. 8.7% of GRI Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares GRI Bio and Seaport Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRI Bio	N/A	N/A	-$11.96 million	($74.16)	-0.02
Seaport Therapeutics	N/A	N/A	-$74.88 million	($12.12)	-2.00

Seaport Therapeutics is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

About GRI Bio

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

About Seaport Therapeutics

Seaport Therapeutics Inc. is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc. is based in BOSTON.